Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CETROTIDE vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (Gn RH) antagonistic activity. It competitively blocks Gn RH receptors on the pituitary gland, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Inhibition of premature LH surges in women undergoing controlled ovarian stimulation for assisted reproductive technology (ART)
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
0.25 mg subcutaneously once daily starting on day 7 of ovarian stimulation and continuing until the day of h CG administration.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal elimination half-life is approximately 36 hours after subcutaneous administration. This long half-life supports once-daily dosing for continuous Gn RH antagonist effect.
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Cetrorelix is metabolized via peptidase cleavage and is primarily eliminated unchanged in urine and feces.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Primarily renal excretion of unchanged drug (approx. 40-50%) and metabolites; remainder excreted in feces via biliary elimination. Total recovery in urine and feces accounts for >90% of dose.
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
Approximately 80% bound to plasma proteins, primarily albumin.
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
Approximately 0.7 L/kg, indicating distribution primarily into extracellular fluid and limited tissue binding.
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
Subcutaneous administration: approximately 85% absolute bioavailability compared to intravenous injection.
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
No specific dose adjustment is recommended for patients with renal impairment; however, caution is advised in severe impairment due to limited data.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
No specific dose adjustment is recommended for patients with hepatic impairment; however, caution is advised in severe impairment due to limited data.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Not indicated for pediatric use; safety and efficacy have not been established.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Not indicated for geriatric use; safety and efficacy have not been established in women over 65 years.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
None.
None.
Hypersensitivity reactions (e.g., anaphylaxis) have been reported.,Ovarian hyperstimulation syndrome (OHSS) may occur; monitor during stimulation.,Use caution in patients with active allergic conditions or history of asthma.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Hypersensitivity to cetrorelix, Gn RH, or any other Gn RH analog.,Known or suspected pregnancy.,Breastfeeding.,Severe renal impairment (creatinine clearance <30 m L/min).,Pre-existing moderate to severe hepatic impairment.
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No known food interactions. No dietary restrictions required.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
Pregnancy Category X. Cetrorelix is contraindicated during pregnancy due to risk of fetal harm. In animal studies, it caused embryolethality and teratogenicity at doses lower than human exposure. No adequate human studies exist.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
No data on cetrorelix excretion in human milk. M/P ratio unknown. Given its peptide nature and short half-life, excretion is unlikely but not confirmed. Caution advised; avoid use in nursing mothers unless clearly needed.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Cetrorelix is contraindicated in pregnancy; no dosing adjustments apply. Dose modifications are not recommended as drug should not be used.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Cetrotide (cetrorelix) is a Gn RH antagonist used in controlled ovarian stimulation to prevent premature LH surges. Administer subcutaneously in the lower abdominal wall; rotate sites. Monitor for ovarian hyperstimulation syndrome (OHSS). Onset of action is immediate; does not cause flare effect like Gn RH agonists. Dose adjustment not required in renal or hepatic impairment. Use with caution in patients with allergies to Gn RH analogs or mannitol.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
Inject exactly as prescribed, at the same time each day during the stimulation cycle.,Do not skip doses; missing a dose may increase risk of premature ovulation.,Report any signs of allergic reaction, such as rash, hives, or difficulty breathing.,Mild injection site reactions (redness, swelling, itching) are common and usually resolve.,Avoid pregnancy prior to the procedure; use non-hormonal contraception if needed.,Understand the risk of OHSS: symptoms include severe pelvic pain, nausea, vomiting, sudden weight gain, and decreased urination.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
No interactions on record
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CETROTIDE vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
CETROTIDE is a GnRH antagonist that works by Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (Gn RH) antagonistic activity. It competitively blocks Gn RH receptors on the pituitary gland, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CETROTIDE and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CETROTIDE is: 0.25 mg subcutaneously once daily starting on day 7 of ovarian stimulation and continuing until the day of h CG administration.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CETROTIDE and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CETROTIDE is classified as Category C. Pregnancy Category X. Cetrorelix is contraindicated during pregnancy due to risk of fetal harm. In animal studies, it caused embryolethality and teratogenicity at doses lower than . ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.